Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model

European Journal of Neuroscience

Volumn 22, Issue 10, 2005, Pages 2587-2595

  Dowd, Eilís ^a   Monville, Christelle ^a   Torres, Eduardo M ^a   Wong, Liang Fong ^b   Azzouz, Mimoun ^b   Mazarakis, Nicholas D ^b   Dunnett, Stephen B ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

6 hydroxydopamine; Lentivirus; Medial forebrain bundle; Parkinson's disease; Reaction time

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; OXIDOPAMINE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; ERROR; FEMALE; INSTRUMENTAL CONDITIONING; LOCOMOTION; MEDIAL FOREBRAIN BUNDLE; MOTOR PERFORMANCE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; STIMULUS RESPONSE; SUBSTANTIA NIGRA; TASK PERFORMANCE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

AMPHETAMINE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BETA-GALACTOSIDASE; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; DOPAMINE AGONISTS; FEMALE; FUNCTIONAL LATERALITY; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MOVEMENT; PARKINSON DISEASE; RATS; REACTION TIME; TYROSINE 3-MONOOXYGENASE;

EID: 28744446884     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2005.04414.x     Document Type: Article

References (43)

1. Azzouz, M., Ralph, S., Wong, L.F., Day, D., Askham, Z., Barber, R.D., Mitrophanous, K.A., Kingsman, S.M. & Mazarakis, N.D. (2004) Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. Neuroreport, 15, 985-990.
2. Bjorklund, A., Dunnett, S.B. & Nikkhah, G. (1994) Nigral transplants in the rat Parkinson model. Functional limitations and strategies to enhance nigrostriatal reconstruction. In Dunnett, S.B. & Bjorklund, A., (Eds), Functional neural transplantation. Raven, New York, pp. 47-68.
3. Bjorklund, A., Kirik, D., Rosenblad, C, Georgievska, B., Lundberg, C. & Mandel, R.J. (2000) Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res., 886, 82-98.
4. Bjorklund, A., Rosenblad, C., Winkler, C. & Kirik, D. (1997) Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis., 4, 186-200.
5. Brooks, D.J. (1998) The early diagnosis of Parkinson's disease. Ann. Neurol., 44, S10-S18.
6. Carli, M., Evenden, J.L. & Robbins, T.W. (1985) Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention. Nature, 313, 679-682.
7. Cousins, M.S. & Salamone, J.D. (1996) Involvement of ventrolateral striatal dopamine in movement initiation and execution: a microdialysis and behavioral investigation. Neuroscience, 70, 849-859.
8. Cousins, M.S., Sokolowski, J.D. & Salamone, J.D. (1993) Different effects of nucleus accumbens and ventrolateral striatal dopamine depletions on instrumental response selection in the rat. Pharmacol. Biochem. Behav., 46, 943-951.
9. Curran, M.A., Kaiser, S.M., Achacoso, P.L. & Nolan, G.P. (2000) Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther., 1, 31-38.
10. Dowd, E. & Dunnett, S.B. (2004) Deficits in a lateralized associative learning task in dopamine-depleted rats with functional recovery by dopamine-rich transplants. Eur. J. Neurosci., 20, 1953-1959.
11. Dowd, E. & Dunnett, S.B. (2005) Comparison of 6-hydroxydopamine- induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats. Behav. Brain Res., 159, 153-161.
12. Dowd, E., Monville, C., Torres, E.M. & Dunnett, S.B. (2005) The corridor task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res. Bull., in press.
13. Dunnett, S.B. & Bjorklund, A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature, 399, A32-A39.
14. Dunnett, S.B. & Iversen, S.D. (1982) Sensorimotor impairments following localized kainic acid and 6-hydroxydopamine lesions of the neostriatum. Brain Res., 248, 121-127.
15. Feamley, J.M. & Lees, A.J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114, 2283-2301.
16. Gash, D.M., Gerhardt, G.A. & Hoffer, B.J. (1998) Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates. Adv. Pharmacol., 42, 911-915.
17. Gash, D.M., Zhang, Z., Ovadia, A., Cass, W.A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P.A., Collins, F., Hoffer, B.J. & Gerhardt, G.A. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature, 380, 252-255.
18. Gauntlett-Gilbert, J. & Brown, V.J. (1998) Reaction time deficits and Parkinson's disease. Neurosci. Biobehav Rev., 22, 865-881.
19. Georgievska, B., Kirik, D. & Bjorklund, A. (2002) Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol., 177, 461-474.
20. Georgievska, B., Kirik, D. & Bjorklund, A. (2004) Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J. Neurosci., 24, 6437-6445.
21. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N. & Heywood, P. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Med., 9, 589-595.
22. Johnston, J.C., Gasmi, M., Lim, L.E., Elder, J.H., Yee, J.K., Jolly, D.J., Campbell, K.P., Davidson, B.L. & Sauter, S.L. (1999) Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol, 73, 4991-5000.
23. Kirik, D., Rosenblad, C. & Bjorklund, A. (1998) Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol., 152, 259-277.
24. Kirik, D., Rosenblad, C. & Bjorklund, A. (2000a) Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci, 12, 3871-3882.
25. Kirik, D., Rosenblad, C., Bjorklund, A. & Mandel, R.J. (2000b) Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci., 20, 4686-4700.
26. Koller, W.C. & Hubble, J.P. (1990) Levodopa therapy in Parkinson's disease. Neurology, 40, 40-47.
27. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N. & Aebischer, P. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290, 767-773.
28. Mackintosh, N.J. (1974) The Psychology of Animal Learning. Academic Press, London.
29. Mazarakis, N.D., Azzouz, M., Rohll, J.B., Ellard, F.M., Wilkes, F.J., Olsen, A.L., Carter, E.E., Barber, R.D., Baban, D.F., Kingsman, S.M., Kingsman, A.J., O'Malley, K. & Mitrophanous, K.A. (2001) Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet., 10, 2109-2121.
30. Mitrophanous, K., Yoon, S., Rohll, J., Patil, D., Wilkes, F., Kim, V, Kingsman, S., Kingsman, A. & Mazarakis, N. (1999) Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther., 6, 1808-1818.
31. Montoya, C.P., Campbell-Hope, L.J., Pemberton, K.D. & Dunnett, S.B. (1991) The 'staircase test': a measure of independent forelimb reaching and grasping abilities in rats. J. Neurosci. Meth., 36, 219-228.
32. Olsson, M., Nikkhah, G., Bentlage, C. & Bjorklund, A. (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci., 15, 3863-3875.
33. Patel, N.K., Bunnage, M., Plaha, P., Svendsen, C.N., Heywood, P. & Gill, S.S. (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol, 57, 298-302.
34. Poeschla, E.M., Wong-Staal, F. & Looney, D.J. (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nature Med., 4, 354-357.
35. Robbins, T.W., Muir, J.L., Killcross, A.S. & Pretsell, D. (1993) Methods for assessing attention and stimulus control in the rat. In Sahgal, A., (Ed), Behavioural Neuroscience; a Practical Approach. IRL Press, Oxford, pp. 13-47.
36. Rosenblad, C., Kirik, D. & Bjorklund, A. (2000) Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol., 161, 503-516.
37. Schallert, T., Norton, D. & Jones, T.A. (1992) A clinically relevant unilateral rat model of Parkinsonian akinesia. J. Neural. Transplant Plast., 3, 332-333.
38. Schallert, T. & Tillerson, J.L. (2000) Intervention strategies for degeneration of dopamine neurons in Parkinsonism: optimizing behavioral assessment of outcome. In Emerich, D.F., Dean, R.L.I. & Sanberg, P.R., (Eds), Central Nervous System Diseases: Innovative Animal Models from Laboratory to Clinic. Humana Press, Totowa, NJ, pp. 131-151.
39. Schultz, W. (2002) Getting formal with dopamine and reward. Neuron, 36, 241-263.
40. Soneoka, Y, Cannon, P.M., Ramsdale, E.E., Griffiths, J.C., Romano, G., Kingsman, S.M. & Kingsman, A.J. (1995) A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucl. Acids Res., 23, 628-633.
41. Tenenbaum, L., Chtarto, A., Lehtonen, E., Blum, D., Baekelandt, V., Velu, T., Brotchi, J. & Levivier, M. (2002) Neuroprotective gene therapy for Parkinson's disease. Curr. Gene Ther., 2, 451-483.
42. Torres, E.M., Rogers, D.C., Annett, L.E., Sirinathsinghji, D.J. & Dunnett, S.B. (1993) A novel population of tyrosine hydroxylase immunoreactive neurones in the basal forebrain of the common marmoset (Callithrix jacchus). Neurosci. Lett., 150, 29-32.
43. Ungerstedt, U. & Arbuthnott, G. W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res., 24, 485-493.